Hematopoietic stem-cell transplantation (HSCT) is the most potent curative therapy for many malignant and non-malignant disorders. Unfortunately, a major complication of HSCT is graft-versus-host disease (GVHD), which is mediated by tissue damage resulting from the conditioning regimens before the transplantation and the alloreaction of dual immune components (activated donor T-cells and recipient's antigen-presenting cells). This tissue damage leads to the release of alarmins and the triggering of pathogen-recognition receptors that activate the innate immune system and subsequently the adaptive immune system. Alarmins, which are of endogenous origin, together with the exogenous pathogen-associated molecular patterns (PAMPs) elicit similar...
Graft versus host disease (GVHD) is a refractory complication of allogeneic hematopoietic stem cell ...
The clinical success of allogeneic hematopoietic stem cell transplantation (HSCT) depends on the app...
Graft-versus-host disease (GVHD) has been the primary limitation to the wider application of allogen...
The use of allogeneic hematopoietic cell transplantation (HCT) has increased as new techniques have ...
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an evidence based- cellular immuno...
Purpose of review The innate immune system is essential in the protection against microbial infect...
The pathogenesis of acute graft versus host disease (GVHD) is multistep process. This review conside...
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for hem...
Graft-versus-host disease (GVHD) and infection are major complications after allogeneic hematopoieti...
This thesis is comprised of two parts, both exploring complications of hematopoietic stem cell trans...
In the time since the first allogeneic hematopoietic stem cell transplantation (HSCT) was performed ...
For over 60 years, hematopoietic stem cell transplantation (HSCT) has been the major curative therap...
"This is a non-final version of an article published in final form in Current Opinion in Hematology ...
Acute graft-versus-host disease (GVHD) remains a major barrier to the wider application of allogenei...
AbstractOver the last 25 years, allogeneic hematopoietic stem cell transplantation (HSCT) has been u...
Graft versus host disease (GVHD) is a refractory complication of allogeneic hematopoietic stem cell ...
The clinical success of allogeneic hematopoietic stem cell transplantation (HSCT) depends on the app...
Graft-versus-host disease (GVHD) has been the primary limitation to the wider application of allogen...
The use of allogeneic hematopoietic cell transplantation (HCT) has increased as new techniques have ...
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an evidence based- cellular immuno...
Purpose of review The innate immune system is essential in the protection against microbial infect...
The pathogenesis of acute graft versus host disease (GVHD) is multistep process. This review conside...
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for hem...
Graft-versus-host disease (GVHD) and infection are major complications after allogeneic hematopoieti...
This thesis is comprised of two parts, both exploring complications of hematopoietic stem cell trans...
In the time since the first allogeneic hematopoietic stem cell transplantation (HSCT) was performed ...
For over 60 years, hematopoietic stem cell transplantation (HSCT) has been the major curative therap...
"This is a non-final version of an article published in final form in Current Opinion in Hematology ...
Acute graft-versus-host disease (GVHD) remains a major barrier to the wider application of allogenei...
AbstractOver the last 25 years, allogeneic hematopoietic stem cell transplantation (HSCT) has been u...
Graft versus host disease (GVHD) is a refractory complication of allogeneic hematopoietic stem cell ...
The clinical success of allogeneic hematopoietic stem cell transplantation (HSCT) depends on the app...
Graft-versus-host disease (GVHD) has been the primary limitation to the wider application of allogen...